DIAGNOSTICS ALGORITHMS IN DENGUE INFECTIONS

Similar documents
SEROLOGICAL DIAGNOSIS OF DENGUE INFECTIONS

Exchange Program. Thailand. Mahidol University. Mahidol-Osaka Center for Infectious Diseases (MOCID) Date: 2013/06/05~2013/07/04

West Nile Virus. By Frank Riusech

ZIKA VIRUS SHIPPING SOLUTIONS

Dengue IgG/IgM/NS1 Combo Rapid Test Device

Arbovirus Reports 2015

Arbovirus Epidemiology and Diagnosis Educational Session Curacao 2016 R. Steingrover Clinical Microbiologist ADC

Centers for Disease Control and Prevention Zika Diagnosis: Challenges and Opportunities

Dengue Virus IgM Elisa kit

4. Laboratory Diagnosis of Viral Haemorrhagic Fever Viruses

Zika virus: laboratory diagnosis

Appendix I (a) Human Surveillance Case Definition (Revised July 4, 2005)

First Probable West Nile Virus Case in the Simcoe-Muskoka Area

Public Health Image Library. CDC/ Cynthia Goldsmith. Image #

1. Dengue An Overview. Dengue Expert Advisory Group

MODULE 5. Dengue. Edwin J. Asturias Associate Professor of Pediatrics Senior Investigator Director for Latin America

What is the role of animal models in studying protective titres and the need for establishing surrogates/correlates of protection?

DENGUE AND BLOOD SAFETY. Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo

Appendix B: Provincial Case Definitions for Reportable Diseases

Indonesia s challenges and needs in improving national capabilities for disease surveillance, detection and diagnosis and public health systems:

Zika Virus Basics. Flaviviridae Flavivirus Disease Vector Vaccine *Dengue (serotypes 1-4) Zika Virus Basics. Zika Virus Transmission Cycle

Case Study: West Nile Virus -Taking an Integrated National Public Health Approach to an Emerging Infectious Disease in Canada

Appendix B: Provincial Case Definitions for Reportable Diseases

Dengue Infection at Children's Hospital of Bangkok

Surveillance for encephalitis in Bangladesh: preliminary results

European Guidelines on Management of Tick Borne Encephalitis: a Focus on Intensive Care

Clinical Utility of Commercial Enzyme Immunoassays during the Inaugural Season of West Nile Virus Activity, Alberta, Canada

Case Classification West Nile Virus Neurological Syndrome (WNNS)

DIAGNOSIS OF DENGUE INFECTION USING VARIOUS DIAGNOSTIC TESTS IN THE EARLY STAGE OF ILLNESS

Measles and Measles Vaccine

The pages that follow contain information critical to protecting the health of your patients and the citizens of Colorado.

Innovation in Diagnostics. ToRCH. A complete line of kits for an accurate diagnosis INFECTIOUS ID DISEASES

Dengue IgG/IgM Dengue IgG and IgM ELISA. Enzyme Linked Immunosorbent Assay. ELISA-Indirect; Antigen Coated Plate

Flavivirus Vaccines Japanese Encephalitis and Dengue

Laboratory Testing for West Nile Virus Infections Testing Human & Non-Human Tissues

Flaviviruses New Challenges, New Vaccines

Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017

Comparison between serological & molecular methods for diagnosis of dengue fever and its correlation with duration of illness

Categorisation of Dengue based on duration of fever and serological markers in a tertiary care hospital

Weekly Influenza Activity: Statistics Summary

Weekly Influenza & Respiratory Activity: Statistics Summary

LABORATORY ALERT: Ebola Virus Disease (EVD)

Dengue Symptoms Significance in Anti-Dengue Drug Development: Road Less Travelled

Dengue: The next vaccine preventable disease? Prof John McBride James Cook University

Appendix B: Provincial Case Definitions for Reportable Diseases

What s Lurking out there??????

The Features of Imported Dengue Fever Cases Confirmed at National Institute of Infectious Diseases Japan, during p

Zika Virus: The Olympics and Beyond

Objectives. Dengue, Chikungunya and Zika Virus Infection: Answers to Common Questions. Case 1. Dengue Introduction 10/15/2018

Rubella virus IgG ELISA Kit

: AccuPower ZIKV(DENV, CHIKV) Multiplex Real-Time RT-PCR Kit. Copyright, Bioneer Corporation. All rights reserved.

Sero-Prevalence of Dengue Infection by Rapid Immunochromatographic Assay from Tertiary Care Medical College Hospital in Coimbatore, India

VIRAL HEMORRHAGIC FEVER (VHF)

Zika Virus in the Primary Care Setting

Adventures in Discordance- HIV Testing

This memo is intended to provide information to NC clinicians and laboratories regarding diagnosis, management and reporting of Zika virus infection.

Haemogram profile of dengue fever in adults during 19 September 12 November 2008: A study of 40 cases from Delhi

ESCMID Online Lecture by author TICK-BORNE ENCEPHALITIS CHANGES OF THE DISEASE INCIDENCE. atjana Avšič Županc

Dengue. (Also Known as Dengue Fever, Dengue Hemorrhagic Fever, and Breakbone Fever)

Human Cytomegalovirus Virus (CMV) IgG ELISA Kit

Dengue IgG ELISA Kit. Cat. No.:DEIA508 Pkg.Size:96T. Intended use. General Description. Principle Of The Test. Reagents And Materials Provided

Human Cytomegalovirus IgM ELISA Kit

CYTOMEGALOVIRUS (CMV) IgM ELISA Kit Protocol

DIAGNOSTIC AUTOMATION, INC.

WHO Prequalification of Diagnostics Programme PUBLIC REPORT

TEST REQUEST INFORMATION- VIROLOGY

Study of Seroprevalence of Dengue Virus Infection in a Tertiary Care Hospital in Patan, Gujarat, India

Geneva, March Consultation background

Module Three About Zika Virus: What is Known and Not Known

J07 Titer dynamics, complement fixation test and neutralization tests

Dengue NS1 Antigen - for Early Detection of Dengue Virus Infection

Mosquitoborne Viral Diseases

Current strategies, initiatives and challenges to mitigate biorisk: Indonesia s experience

Development and Persistence of West Nile Virus-Specific Immunoglobulin M (IgM), IgA, and IgG in Viremic Blood Donors

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)

Outbreak Investigation Guidance for Vectorborne Diseases

OIE Reference Laboratory Reports Activities

A study of NS1 antigen and platelet count for early diagnosis of dengue infection

Update on Transfusion- Transmitted Infectious Diseases

Prevention of transfusion-transmitted arboviruses in French Polynesia

WHO Emergency Use Assessment and Listing (EUAL) Procedure. Robyn Meurant WHO PQ Team Diagnostics Assessment

Zika virus infection Interim clinical guidance for Primary Care

Dengue Stephen J. Thomas, MD Director, Viral Diseases Branch Walter Reed Army Institute of Research (WRAIR) 14 AUG 2012

TISSUE COLLECTION. SCPA 603- Histopathological Techniques for Routine and Research

Gastroenteritis and viral infections

Dengue virus infection: Incidence among Long Term Travelers

Everything you ever wanted to know about Zika Virus Disease

World Health Organization Collaborating Centre for Reference and Research on Viral Haemorrhagic Fevers & Arboviruses

The Alphabet Soup of Viral Hepatitis Testing

Laboratory Investigations During Nipah Virus Outbreak in Kerala work done and gaps identified

Zika Virus Guidance for Medical Providers. Denise Smith, PHN, MPA Director of Disease Control Kern County Public Health Services Department

Establishment of networks of human and animal virology laboratories and medical entomology

Rubella Latex Agglutination Test

Updates in Infectious Diseases. Kelley Struble, DO, MS St. John Physicians Infectious Disease September 30, 2016

CDIA TM Rubella IgG/IgM Rapid Test Kit

Received 11 July 2011/Returned for modification 27 August 2011/Accepted 11 October 2011

PCR Is Not Always the Answer

Hepa%%s E Virus Is it a Concern?

Outbreak investigation in vector-borne Diseases

Emerging TTIs How Singapore secure its blood supply

Transcription:

ECDC training Workshop on laboratory diagnosis of dengue virus infections Berlin, 23 27 January 2012 DIAGNOSTICS ALGORITHMS IN DENGUE INFECTIONS Cristina Domingo Carrasco Robert Koch Institut

KINETICS OF VIRUS REPLICATION AND HOST RESPONSE FEVER Viral dissemination Antibodies in serum Viremia The patterns of viremia and immune response after dengue infection are different in primary and secondary infections

KINETICS OF VIRUS REPLICATION AND HOST RESPONSE IN PRIMARY INFECTIONS 99% 80% Guzmán MG, Nature Reiews, 2010 The physiological definition of a primary infection is one characterized by a high molar fraction of anti dengue IgM and low molar fraction of anti dengue IgG

KINETICS OF VIRUS REPLICATION AND HOST RESPONSE IN PRIMARY INFECTIONS CROSS REACTING ANTIBODIES SEROTYPING ANTIBODIES 90 Specimens obtained during late convalescence from patients with a primary seroresponse pattern may be useful for serotyping

KINETICS OF VIRUS REPLICATION AND HOST RESPONSE IN SECONDARY (ANAMNESTIC) INFECTIONS PRIMARY INFECTION SECONDARY INFECTION 0 1 2 3 4 5 6 7 8 9 10 15 30 90 Viremia IgM IgG 0 1 2 3 4 5 6 7 8 9 10 15 30 90 Viremia IgM IgG The physiological definition of a secondary infection isone characterized by a low molar fraction of anti dengue IgM and a high molar fraction of IgG broadly reactive to flaviviruses

KINETICS OF VIRUS REPLICATION AND HOST RESPONSE IN SECONDARY (ANAMNESTIC) INFECTIONS ANTIBODIES SEROTYPE 1st DENGUE CROSS REACTING ANTIBODIES 0 1 2 3 4 5 6 7 8 9 10 15 30 90 Viremia IgM IgG The physiological definition of a secondary infection isone characterized by a low molar fraction of anti dengue IgM and a high molar fraction of IgG broadly reactive to flaviviruses

KINETICS OF VIRUS REPLICATION AND HOST RESPONSE DIAGNOSTIC ALGORITHMS NS1 antigen D. NS1 antigen D. SEROLOGY SEROLOGY MOLECULAR D. MOLECULAR D VIRAL ISOLATION VIRAL ISOLATION 0 1 2 3 4 5 6 7 8 9 10 15 30 90 0 1 2 3 4 5 6 7 8 9 10 15 30 90 Viremia IgM IgG Viremia IgM IgG PRIMARY INFECTIONS SECONDARY INFECTIONS Domingo C., de Ory F., Sanz J.C., et al. Diagnostic Microbiol. and Infect. Dis. 2009

WHEN A SECONDARY INFECTION SHOULD BE CONSIDERED? Presence of IgG 2 3 days after onset together with viral genome or NS1 antigen HOW TO DISCRIMINATE BETWEEN PRIMARY AND SECONDARY DENGUE INFECTION? IgM/IgG ratio Avidity index Domingo et al, Diagn. Microbiol. Infect. Dis., 2009 Influence of previous flavivirus vaccines in the serological profile

Time dependent discriminatory power of the IgM/IgG ratio and the avidity test 110 IgG corrected avidity index 100 90 80 70 60 50 40 30 PRIMARY SECONDARY R 2 = 0,045 R 2 = 0,21 20 10 0 Days of evolution 0 5 10 15 20 25 30 35 40 45 50 IgG avidity corrected index in primary dengue confirmed cases (22 samples) and secondary dengue confirmed cases (15 samples) plotted against days after start of symptoms Domingo C. et al, Diagn. Microbiol. Infect. Dis., 2009

KINETICS OF VIRUS REPLICATION AND HOST RESPONSE INFLUENCE OF PREVIOUS VACCINATIONS YELLOW FEVER VACCINE JAPANESE ENCEPHALITIS VACCINE TRAVELLERS TICK BORNE ENCEPHALITIS EUROPEANS

ACUTE DENGUE CASE CLASSIFICATION CONFIRMED PRIMARY ACUTE DENGUE CONFIRMED SECONDARY ACUTE DENGUE PCR NS1 antigen IgM IgG + + + + + + + + +/ +/ + IgM/IgG ratio <1.8 2 IgG avidity index >50% PCR NS1 antigen IgM IgG + /+ +* + + /+ +* + +* * In the absence of previous flavivirus vaccination PROBABLE SECONDARY ACUTE DENGUE* PCR NS1 antigen IgM IgG + + + + + * SAMPLE < 10 days post onset

WHICH SAMPLES ARE SUITABLE? Genome detection and virus isolation: serum, plasma, blood, CSF, tissues Antigen detection: serum, tissues Specific antibodies: serum, CSF WHEN SHOULD THE SAMPLES BE COLLECTED? As soon as possible The collection of paired samples, optimal 10 days apart, must be encouraged to confirm or refute acute dengue diagnosis In the envent of a fatality at the time of death HOW MUST THE SAMPLES BE COLLECTED? Aseptically Identify the samples with patient ID, date of collection, type of sample Use screw cap tubes preferably For genome detection avoid heparin or EDTA

HOW MUST THE SAMPLES BE STORED AFTER COLLECTION? During the first 24h after collection: 4 C but preferably 80 C or 20 C More than 24h after collection: Viral isolation: 80 C Genome: storage short time 20 C ( 40 80 C preferred) Antigen/antibody detection: 20 C WHICH ARE THE BIOSAFETY REQUIREMENTS FOR SAMPLE TRANSPORT? Dengue is a BSL 3 pathogen in Europe Sample transport must be done following current normative for infectious clinical specimens (double package, dessicant, absorbent material, labelling ) OPTION: The samples can be sent in specific buffers (AVL buffer, RNA later buffer, QIAGEN): inactivation of the pathogen plus protection RNA

WHICH ARE THE BIOSAFETY REQUIREMENTS FOR SAMPLE MANIPULATION ON ARRIVAL? Viral isolation of samples suspected of dengue infection must be performed in BSL 3 facilities Sample preparation and inactivation for molecular or serological diagnosis could be performed in BSL 2 facilities under Class II biosecurity laminarflow and personal protection measures (double pair of gloves, mask, lab coat ) Inactivate the samples under the laminar flow using suitable buffers or by heating at 56 C during 1h for use in serological assays (only sera) Special consideration for samples of DHF cases coming from VHF endemic areas

WHICH INFORMATION DOES THE LABORATORY NEED FOR FURTHER INTERPRETATION OF THE RESULTS? Mandatory: Date of onset of illness Date of sample collection Travel history (country, dates ) Contact physician Recommended: Other diagnosis Previous flavivirus infections orvaccinations Nationality History of previous travel to endemic areas Previous fever episodes after travel Concise clinical findings Age